case_images: PMC11034688_01
case_images: External eye photo of the patient after afatinib use, featuring a direct examination of bilateral corneas with and without fluorescein staining. (OD) Displays diffuse superficial punctate keratopathy at the cornea's central region. (OS) Exhibits a 10 mm x 4 mm epithelial defect (ED) spanning from the central to the 6 o'clock direction
case_images: TJO-14-121-g001.jpg
case_images: PMC11034688_01_TJO-14-121-g001.jpg
case_images: TJO-D-24-00003-f001
case_images: Slit-lamp examination and fluorescent stain showed that the right cornea displayed a diffuse superficial punctate keratopathy (SPK), which was extended from the central to the lower half of the cornea, and the left cornea presented a 10 mm x 4 mm epithelial defect (ED) spanning from the central to the 6 o'clock direction [Figure 1].
case_images: External eye photo of the patient 1 week after tapering afatinib. (OD) Showed reduced extent of superficial punctate keratopathy and a new 1.5 mm x 2 mm epithelial defect (ED) at 6 o'clock. (OS) Demonstrated a reduction in the initial ED size
case_images: TJO-14-121-g002.jpg
case_images: PMC11034688_01_TJO-14-121-g002.jpg
case_images: TJO-D-24-00003-f002
case_images: Approximately 1 week after reverting afatinib dosage, bilateral SPK had reduced in extent, but a 1.5 mm x 3 mm ED had developed in the right eye and another 1.5 mm x 2 mm ED had developed in the left eye [Figure 2].
case_images: External eye photo of the patient 2 weeks after tapering afatinib. Significant resolution of bilateral superficial punctate keratopathy and epithelial defect in both eyes (OU)
case_images: TJO-14-121-g003.jpg
case_images: PMC11034688_01_TJO-14-121-g003.jpg
case_images: TJO-D-24-00003-f003